Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 114(38): 10107-10112, 2017 09 19.
Article in English | MEDLINE | ID: mdl-28864529

ABSTRACT

An effect of thyroid hormone (TH) on erythropoiesis has been known for more than a century but the molecular mechanism(s) by which TH affects red cell formation is still elusive. Here we demonstrate an essential role of TH during terminal human erythroid cell differentiation; specific depletion of TH from the culture medium completely blocked terminal erythroid differentiation and enucleation. Treatment with TRß agonists stimulated premature erythroblast differentiation in vivo and alleviated anemic symptoms in a chronic anemia mouse model by regulating erythroid gene expression. To identify factors that cooperate with TRß during human erythroid terminal differentiation, we conducted RNA-seq in human reticulocytes and identified nuclear receptor coactivator 4 (NCOA4) as a critical regulator of terminal differentiation. Furthermore, Ncoa4-/- mice are anemic in perinatal periods and fail to respond to TH by enhanced erythropoiesis. Genome-wide analysis suggests that TH promotes NCOA4 recruitment to chromatin regions that are in proximity to Pol II and are highly associated with transcripts abundant during terminal differentiation. Collectively, our results reveal the molecular mechanism by which TH functions during red blood cell formation, results that are potentially useful to treat certain anemias.


Subject(s)
Cell Differentiation , Nuclear Receptor Coactivators/metabolism , Reticulocytes/metabolism , Thyroid Hormone Receptors beta/metabolism , Thyroid Hormones/metabolism , Animals , Chromatin/genetics , Chromatin/metabolism , Genome-Wide Association Study , Humans , Mice , Mice, Knockout , Nuclear Receptor Coactivators/genetics , Thyroid Hormone Receptors beta/genetics , Thyroid Hormones/genetics
2.
Blood ; 128(23): 2637-2641, 2016 12 08.
Article in English | MEDLINE | ID: mdl-27777239

ABSTRACT

Burst-forming unit erythroid progenitors (BFU-Es) are so named based on their ability to generate in methylcellulose culture large colonies of erythroid cells that consist of "bursts" of smaller erythroid colonies derived from the later colony-forming unit erythroid progenitor erythropoietin (Epo)-dependent progenitors. "Early" BFU-E cells forming large BFU-E colonies presumably have higher capacities for self-renewal than do "late" BFU-Es forming small colonies, but the mechanism underlying this heterogeneity remains unknown. We show that the type III transforming growth factor ß (TGF-ß) receptor (TßRIII) is a marker that distinguishes early and late BFU-Es. Transient elevation of TßRIII expression promotes TGF-ß signaling during the early BFU-E to late BFU-E transition. Blocking TGF-ß signaling using a receptor kinase inhibitor increases early BFU-E cell self-renewal and total erythroblast production, suggesting the usefulness of this type of drug in treating Epo-unresponsive anemias.


Subject(s)
Antigens, Differentiation/metabolism , Erythrocytes/metabolism , Erythroid Precursor Cells/metabolism , Proteoglycans/metabolism , Receptors, Transforming Growth Factor beta/metabolism , Signal Transduction/physiology , Transforming Growth Factor beta/metabolism , Anemia/metabolism , Anemia/therapy , Animals , Erythrocytes/cytology , Erythroid Precursor Cells/cytology , Erythropoietin/metabolism , Humans , Mice
3.
Nature ; 522(7557): 474-7, 2015 Jun 25.
Article in English | MEDLINE | ID: mdl-25970251

ABSTRACT

Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit erythroid progenitors (CFU-Es) that respond to Epo are either too few in number or are not sensitive enough to Epo to maintain sufficient red blood cell production. Treatment of these anaemias requires a drug that acts at an earlier stage of red cell formation and enhances the formation of Epo-sensitive CFU-E progenitors. Recently, we showed that glucocorticoids specifically stimulate self-renewal of an early erythroid progenitor, burst-forming unit erythroid (BFU-E), and increase the production of terminally differentiated erythroid cells. Here we show that activation of the peroxisome proliferator-activated receptor α (PPAR-α) by the PPAR-α agonists GW7647 and fenofibrate synergizes with the glucocorticoid receptor (GR) to promote BFU-E self-renewal. Over time these agonists greatly increase production of mature red blood cells in cultures of both mouse fetal liver BFU-Es and mobilized human adult CD34(+) peripheral blood progenitors, with a new and effective culture system being used for the human cells that generates normal enucleated reticulocytes. Although Ppara(-/-) mice show no haematological difference from wild-type mice in both normal and phenylhydrazine (PHZ)-induced stress erythropoiesis, PPAR-α agonists facilitate recovery of wild-type but not Ppara(-/-) mice from PHZ-induced acute haemolytic anaemia. We also show that PPAR-α alleviates anaemia in a mouse model of chronic anaemia. Finally, both in control and corticosteroid-treated BFU-E cells, PPAR-α co-occupies many chromatin sites with GR; when activated by PPAR-α agonists, additional PPAR-α is recruited to GR-adjacent sites and presumably facilitates GR-dependent BFU-E self-renewal. Our discovery of the role of PPAR-α agonists in stimulating self-renewal of early erythroid progenitor cells suggests that the clinically tested PPAR-α agonists we used may improve the efficacy of corticosteroids in treating Epo-resistant anaemias.


Subject(s)
Erythroid Precursor Cells/cytology , Erythropoiesis , PPAR alpha/metabolism , Receptors, Glucocorticoid/metabolism , Acute Disease , Anemia/drug therapy , Anemia/metabolism , Anemia/pathology , Anemia, Hemolytic/metabolism , Animals , Butyrates/pharmacology , Butyrates/therapeutic use , Cell Culture Techniques , Cells, Cultured , Chromatin/genetics , Chromatin/metabolism , Chronic Disease , Disease Models, Animal , Erythroid Precursor Cells/drug effects , Erythroid Precursor Cells/metabolism , Erythropoiesis/drug effects , Erythropoietin/pharmacology , Female , Fenofibrate/pharmacology , Glucocorticoids/pharmacology , Humans , Liver/cytology , Liver/drug effects , Liver/embryology , Mice , PPAR alpha/agonists , PPAR alpha/deficiency , Phenylhydrazines/pharmacology , Phenylurea Compounds/pharmacology , Phenylurea Compounds/therapeutic use , Signal Transduction/drug effects
4.
J Neurosci ; 33(30): 12543-52, 2013 Jul 24.
Article in English | MEDLINE | ID: mdl-23884957

ABSTRACT

Chronic pain associated with injury or disease can result from dysfunction of sensory afferents whereby the threshold for activation of pain-sensing neurons (nociceptors) is lowered. Neurotrophic factors control nociceptor development and survival, but also induce sensitization through activation of their cognate receptors, attributable, in part, to the modulation of ion channel function. Thermal pain is mediated by channels of the transient receptor potential (TRP) family, including the cold and menthol receptor TRPM8. Although it has been shown that TRPM8 is involved in cold hypersensitivity, the molecular mechanisms underlying this pain modality are unknown. Using microarray analyses to identify mouse genes enriched in TRPM8 neurons, we found that the glial cell line-derived neurotrophic factor (GDNF) family receptor GFRα3 is expressed in a subpopulation of TRPM8 sensory neurons that have the neurochemical profile of cold nociceptors. Moreover, we found that artemin, the specific GFRα3 ligand that evokes heat hyperalgesia, robustly sensitized cold responses in a TRPM8-dependent manner in mice. In contrast, GFRα1 and GFRα2 are not coexpressed with TRPM8 and their respective ligands GDNF and neurturin did not induce cold pain, whereas they did evoke heat hyperalgesia. Nerve growth factor induced mild cold sensitization, consistent with TrkA expression in TRPM8 neurons. However, bradykinin failed to alter cold sensitivity even though its receptor expresses in a subset of TRPM8 neurons. These results show for the first time that only select neurotrophic factors induce cold sensitization through TRPM8 in vivo, unlike the broad range of proalgesic agents capable of promoting heat hyperalgesia.


Subject(s)
Chronic Pain/physiopathology , Cold Temperature/adverse effects , Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism , Nerve Tissue Proteins/metabolism , TRPM Cation Channels/genetics , Animals , Chronic Pain/genetics , Female , Ganglia, Spinal/cytology , Ganglia, Spinal/physiology , Glial Cell Line-Derived Neurotrophic Factor Receptors/genetics , Hot Temperature , Hyperalgesia/genetics , Hyperalgesia/physiopathology , Male , Mice , Mice, Knockout , Nerve Tissue Proteins/genetics , Nociception/physiology , Oligonucleotide Array Sequence Analysis , Sensory Receptor Cells/physiology , TRPM Cation Channels/metabolism , Transcriptional Activation/physiology , Trigeminal Ganglion/cytology , Trigeminal Ganglion/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...